Literature DB >> 30703359

BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade.

Neda Nikbakht1, Manoela Tiago2, Dan A Erkes2, Inna Chervoneva3, Andrew E Aplin4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30703359      PMCID： PMC6591077          DOI： 10.1016/j.jid.2018.12.024

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  14 in total

1.  BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.

Authors:  Miguel F Segura; Bárbara Fontanals-Cirera; Avital Gaziel-Sovran; María V Guijarro; Doug Hanniford; Guangtao Zhang; Pilar González-Gomez; Marta Morante; Luz Jubierre; Weijia Zhang; Farbod Darvishian; Michael Ohlmeyer; Iman Osman; Ming-Ming Zhou; Eva Hernando
Journal:  Cancer Res       Date:  2013-08-15       Impact factor: 12.701

2.  Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade.

Authors:  Shawn D Blackburn; Haina Shin; Gordon J Freeman; E John Wherry
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

3.  Epigenetic manipulation restores functions of defective CD8⁺ T cells from chronic viral infection.

Authors:  Fuqin Zhang; Xiaohui Zhou; Joanna R DiSpirito; Chuan Wang; Ying Wang; Hao Shen
Journal:  Mol Ther       Date:  2014-05-27       Impact factor: 11.454

4.  BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

Authors:  Hengrui Zhu; Fee Bengsch; Nikolaos Svoronos; Melanie R Rutkowski; Benjamin G Bitler; Michael J Allegrezza; Yuhki Yokoyama; Andrew V Kossenkov; James E Bradner; Jose R Conejo-Garcia; Rugang Zhang
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423

5.  Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.

Authors:  Manuelle Viguier; Fabrice Lemaître; Olivier Verola; Min-Sun Cho; Guy Gorochov; Louis Dubertret; Hervé Bachelez; Philippe Kourilsky; Laurent Ferradini
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

6.  BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models.

Authors:  Yuki Kagoya; Munehide Nakatsugawa; Yuki Yamashita; Toshiki Ochi; Tingxi Guo; Mark Anczurowski; Kayoko Saso; Marcus O Butler; Cheryl H Arrowsmith; Naoto Hirano
Journal:  J Clin Invest       Date:  2016-08-22       Impact factor: 14.808

7.  The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

Authors:  Katrina Meeth; Jake Xiao Wang; Goran Micevic; William Damsky; Marcus W Bosenberg
Journal:  Pigment Cell Melanoma Res       Date:  2016-08-03       Impact factor: 4.693

8.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

9.  The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.

Authors:  Alexander S Baras; Charles Drake; Jen-Jane Liu; Nilay Gandhi; Max Kates; Mohamed O Hoque; Alan Meeker; Noah Hahn; Janis M Taube; Mark P Schoenberg; George Netto; Trinity J Bivalacqua
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

10.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Authors:  H R Ali; E Provenzano; S-J Dawson; F M Blows; B Liu; M Shah; H M Earl; C J Poole; L Hiller; J A Dunn; S J Bowden; C Twelves; J M S Bartlett; S M A Mahmoud; E Rakha; I O Ellis; S Liu; D Gao; T O Nielsen; P D P Pharoah; C Caldas
Journal:  Ann Oncol       Date:  2014-06-09       Impact factor: 32.976
View more
  4 in total

1.  PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.

Authors:  Dan A Erkes; Sheera R Rosenbaum; Conroy O Field; Inna Chervoneva; Jessie Villanueva; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2019-12-11       Impact factor: 4.693

2.  The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.

Authors:  Dan A Erkes; Conroy O Field; Claudia Capparelli; Manoela Tiago; Timothy J Purwin; Inna Chervoneva; Adam C Berger; Edward J Hartsough; Jessie Villanueva; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2019-05-20       Impact factor: 4.693

Review 3.  Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.

Authors:  Enyong Dai; Zhi Zhu; Shudipto Wahed; Zhaoxia Qu; Walter J Storkus; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2021-12-20       Impact factor: 41.444

4.  BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.

Authors:  Olga Gusyatiner; Pierre Bady; Minh D T Pham; Yvonne Lei; Jungyeon Park; Roy T Daniel; Mauro Delorenzi; Monika E Hegi
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 12.300
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.